Aligos Therapeutics ($ALGS)
ALGS Overview
Aligos Therapeutics, a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis.Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. (From: StockAnalysis.com)
MORE ABOUT Aligos Therapeutics
Stay up to date with the best of Bullish each week.
BULLISH WEEKLY
Stay up to date with the best of Bullish each week.